Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Health Policy Legislation topic
No spam. Unsubscribe anytime.
Massachusetts law broadens HPC powers, creates Office of Pharmaceutical Policy and Analysis
Summary
Two bills signed Jan. 8 expand the Health Policy Commission's oversight, add board appointments and stipends, create an Office of Pharmaceutical Policy and Analysis to study drug spending and access, and authorize PBM licensing and copay limits for certain drugs in fully insured plans.
The Health Policy Commission on the first public board meeting of 2025 outlined how two recently signed health care bills will expand the agency’s authority and create a new state office focused on prescription drug policy.
Executive Director David SS told commissioners the legislation—signed at the state house on Jan. 8—“in our estimation these two bills represent the most meaningful and significant advancement of Health Care policy and um since the passage of 224 um in terms of our state's oversight uh Authority.” The new law gives the HPC broader market‑oversight powers and directs the agency to stand up an Office of Pharmaceutical Policy and Analysis (OPA) to collect, analyze and report on pharmaceutical spending and access.
Why it matters: the bills bundle several changes that staff said together strengthen the state’s ability to spot market risks, probe transactions that may affect access, and examine the role of manufacturers, pharmacy benefit managers (PBMs) and other intermediaries in driving drug costs.
Key changes and how they work
Board and governance: Effective July 1, 2025, the law revises HPC’s board composition and appointing authorities, adds two new designated commissioners (one with hospital/system expertise and one with pharmaceuticals/biotech/device expertise), and replaces one ex‑officio seat with the Commissioner of Insurance. The statute continues conflict‑of‑interest rules and adds a stipend for members; terms and staggering will be set by the appointing authorities.
Office of Pharmaceutical Policy and Analysis (OPA): OPA will sit inside the HPC, with a mandate to collect detailed spending and plan‑design data, publish an annual report on pharmaceutical access and plan design, and issue targeted analyses and recommendations to the Legislature and state agencies. Staff said OPA’s work will complement existing review tools such as cost and market impact reviews and MassHealth supplemental rebate analyses.
PBM licensing and copay limits: The law directs the Division of Insurance to create a licensing and oversight regime for PBMs operating in Massachusetts (including audit authority and possible license revocation for violations). It also includes a provision that caps out‑of‑pocket costs for certain drugs treating asthma, diabetes and common heart conditions; general counsel Lois clarified that the cap applies to MassHealth, the Group Insurance Commission and any fully insured commercial plans licensed by the Division of Insurance, but does not reach ERISA‑exempt self‑insured employer plans.
Expanded data and enforcement authorities: The law broadens RPO (Registration of Provider Organizations) reporting thresholds to $25 million in revenue from any payer (previously measured differently), increases penalties for noncompliance with reporting rules, and authorizes HPC to require post‑transaction reporting for five years after certain material change notices.
Market oversight expansion: HPC may now require more detailed financial disclosures from significant equity investors and other parties in transactions and will review a wider set of transactions (including asset sales, real estate deals and conversions from nonprofit to for‑profit status) that could affect access and costs.
Staffing and funding: Commissioners asked whether the new mandates come with additional state dollars. David SS said the agency expects OPA and the health resource planning responsibilities will require additional staff and expertise; the law also broadens the industries that contribute to HPC’s operating assessment (including pharmaceutical manufacturers and PBMs), but the agency’s annual budget will continue to be set through the state budget process.
Next steps: Staff said implementation will require new definitions, regulatory work and interagency coordination; many changes take effect April 8 (some provisions) and board and assessment changes are effective July 1, 2025. HPC staff committed to regular updates and to returning to the board with detailed implementation plans.
Sources: presentation and Q&A at the Health Policy Commission public meeting (Jan. 2025).
